JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266047

Human UBQLN1 (Ubiquilin) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UBQLN1 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1.

View Alternative Names

DA41, FLJ90054, PLIC-1, Protein linking IAP with cytoskeleton 1, UBQL1_HUMAN, UBQLN1, UBQN, Ubiquilin-1, XDRP1, hPLIC-1

2 Images
Sanger Sequencing - Human UBQLN1 (Ubiquilin) knockout HeLa cell line (AB266047)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBQLN1 (Ubiquilin) knockout HeLa cell line (AB266047)

Allele-1 : 2 bp deletion in exon 1

Sanger Sequencing - Human UBQLN1 (Ubiquilin) knockout HeLa cell line (AB266047)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBQLN1 (Ubiquilin) knockout HeLa cell line (AB266047)

Allele-2 : 1 bp insertion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266047-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266047 Human UBQLN1 (Ubiquilin) knockout HeLa cell line", "number":"AB266047-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266047-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266047 Human UBQLN1 (Ubiquilin) knockout HeLa cell line", "number":"AB266047-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UBQLN1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Ubiquilin also known as UBQLN1 is a protein that plays a significant role in protein quality control processes. It has a molecular mass of approximately 62 kDa. Ubiquilin is widely expressed in various human tissues notably in the brain heart and skeletal muscle. It facilitates the delivery of misfolded proteins to the proteasome for degradation assisting in maintaining protein homeostasis. This function is essential in preventing the accumulation of dysfunctional proteins which could otherwise be toxic to cells.
Biological function summary

Ubiquilin/UBQLN1 serves as a shuttle factor a component in the intricate network regulating protein degradation. It associates with ubiquitinated proteins and guides them to proteasomes or autophagosomes for disposal. Moreover Ubiquilin forms a complex with heat shock proteins and proteasome components enhancing its role in managing cellular protein quality control. Its activity actively influences proteostasis ensuring the careful balance of protein synthesis and breakdown.

Pathways

Ubiquilin/UBQLN1 is integral to the ubiquitin-proteasome system and autophagy pathways. In these pathways Ubiquilin partners with proteins such as ubiquitin ligases and various adaptor proteins to mediate the clearance of misfolded or excess proteins therefore preventing cellular damage. Its interaction with the chaperone HSP70 is critical for delivering proteins tagged for degradation. Through these pathways Ubiquilin influences cellular stress responses and protein turnover maintaining cellular function and health.

Abnormalities in Ubiquilin/UBQLN1 have been associated with neurodegenerative diseases and cancer. Altered UBQLN1 function or expression contributes to Alzheimer's disease linked to protein aggregation and neuronal damage. Additionally mutations or dysregulation of UBQLN1 are observed in certain cancers where disrupted protein homeostasis promotes tumorigenesis. Here it's involvement with proteins like presenilin-1 and the amyloid precursor protein emphasizes its contributions to disease states making it a focus for therapeutic research.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com